(Q37081944)

English

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial

scientific article published on 16 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1 reference

based on heuristic

inferred from title

author name string

H Yang

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

X Zong

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Y Yu

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

G Shao

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

L Zhang

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

C Qian

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Y Bian

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

X Xu

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

W Sun

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

X Meng

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

X Ding

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

D Chen

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

D Zou

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

S Xie

14

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Y Zheng

15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

J Zhang

16

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

X He

17

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

C Sun

18

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

X Yu

19

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

J Ni

20

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

16 July 2013

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

109

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

582-588

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

ACP Journal Club. Review: Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Tamoxifen for early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

29 September 2017

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

27 June 2018

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

3 September 2018

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

3 September 2018

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

3 September 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

3 September 2018

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

3 September 2018

Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

3 September 2018

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

3 September 2018

Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738136

3 September 2018

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.324

21 January 2018

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.324

21 January 2018

Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.324

21 January 2018

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.324

21 January 2018

A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo - a substudy for IBIS I Breast Cancer Prevention Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23860520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23860520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23860520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.324

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BJC.2013.324

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37081944&oldid=2199846505"